tiprankstipranks
Advertisement
Advertisement

AU:LTP Stock Latest News

LTR Pharma Issues Unquoted Performance Rights Under Employee Incentive Scheme
Company AnnouncementsLTR Pharma Issues Unquoted Performance Rights Under Employee Incentive Scheme
8d ago
LTP
LTR Pharma Wins Ethics Nod for First GI Trial of Intranasal OROFLOW
PremiumCompany Announcements
LTR Pharma Wins Ethics Nod for First GI Trial of Intranasal OROFLOW
24d ago
LTP
LTR Pharma sets first U.S. telehealth route to market for ROXUS
PremiumCompany Announcements
LTR Pharma sets first U.S. telehealth route to market for ROXUS
1M ago
LTP
LTR Pharma outlines limits and legal caveats in latest investor update
PremiumCompany Announcements
LTR Pharma outlines limits and legal caveats in latest investor update
3M ago
LTP
LTR Pharma Halts Trading Ahead of Interim SPONTAN Nasal Spray Trial Results
PremiumCompany Announcements
LTR Pharma Halts Trading Ahead of Interim SPONTAN Nasal Spray Trial Results
3M ago
LTP
LTR Pharma advances SPONTAN Phase II study and U.S. ED spray strategy
PremiumCompany AnnouncementsLTR Pharma advances SPONTAN Phase II study and U.S. ED spray strategy
3M ago
LTP
LTR Pharma issues cautionary investor update on non-offer presentation
Premium
Company Announcements
LTR Pharma issues cautionary investor update on non-offer presentation
4M ago
LTP
LTR Pharma completes recruitment for key Phase II SPONTAN study
Premium
Company Announcements
LTR Pharma completes recruitment for key Phase II SPONTAN study
5M ago
LTP
LTR Pharma lodges half-year Appendix 4D report with ASX
PremiumCompany Announcements
LTR Pharma lodges half-year Appendix 4D report with ASX
5M ago
LTP
LTR Pharma Seeks ASX Quotation for Additional 50,000 Shares
PremiumCompany Announcements
LTR Pharma Seeks ASX Quotation for Additional 50,000 Shares
5M ago
LTP
LTR Pharma Advances ED Nasal Spray Programs as SPONTAN Use Tops 1,000 Prescriptions
PremiumCompany Announcements
LTR Pharma Advances ED Nasal Spray Programs as SPONTAN Use Tops 1,000 Prescriptions
6M ago
LTP
LTR Pharma Begins Phase II Dosing for Intranasal Erectile Dysfunction Spray SPONTAN
PremiumCompany Announcements
LTR Pharma Begins Phase II Dosing for Intranasal Erectile Dysfunction Spray SPONTAN
6M ago
LTP
LTR Pharma Seeks ASX Quotation for Additional 82,508 Shares
PremiumCompany AnnouncementsLTR Pharma Seeks ASX Quotation for Additional 82,508 Shares
6M ago
LTP
LTR Pharma Issues 8.3 Million Unquoted Options Expiring in 2028
Premium
Company Announcements
LTR Pharma Issues 8.3 Million Unquoted Options Expiring in 2028
6M ago
LTP
LTR Pharma Begins Phase II Recruitment for Intranasal Erectile Dysfunction Spray SPONTAN
Premium
Company Announcements
LTR Pharma Begins Phase II Recruitment for Intranasal Erectile Dysfunction Spray SPONTAN
6M ago
LTP
LTR Pharma’s SPONTAN Nasal Spray Data Wins Podium Slot at 2026 Sexual Medicine Congress
PremiumCompany Announcements
LTR Pharma’s SPONTAN Nasal Spray Data Wins Podium Slot at 2026 Sexual Medicine Congress
6M ago
LTP
LTR Pharma Issues New Unquoted Performance Rights and Options Under Incentive Schemes
PremiumCompany Announcements
LTR Pharma Issues New Unquoted Performance Rights and Options Under Incentive Schemes
7M ago
LTP
LTR Pharma Achieves Milestone with SPONTAN® Prescriptions
PremiumCompany Announcements
LTR Pharma Achieves Milestone with SPONTAN® Prescriptions
7M ago
LTP
LTR Pharma Receives TGA Clearance for SPONTAN® Phase II Study
PremiumCompany Announcements
LTR Pharma Receives TGA Clearance for SPONTAN® Phase II Study
7M ago
LTP
LTR Pharma Advances SPONTAN® Phase II Clinical Study with Ethics Approval
PremiumCompany AnnouncementsLTR Pharma Advances SPONTAN® Phase II Clinical Study with Ethics Approval
8M ago
LTP
LTR Pharma to Release Securities from ASX Escrow, Enhancing Market Liquidity
Premium
Company Announcements
LTR Pharma to Release Securities from ASX Escrow, Enhancing Market Liquidity
8M ago
LTP
LTR Pharma Director Acquires 1 Million Options Under Incentive Plan
Premium
Company Announcements
LTR Pharma Director Acquires 1 Million Options Under Incentive Plan
8M ago
LTP

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >